We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




HPV Testing Offers Women Longer Protection than Smear Testing

By Labmedica staff writers
Posted on 21 May 2008
Testing for human papillomavirus (HPV) can be twice as effective at protecting women from developing cervical abnormalities as smear testing.

Nearly 3000 women aged 35+ were recruited into a study between April 1994 and September 1997. More...
They were asked to participate in the study in which HPV testing would be performed in addition to cytology (smear test) whilst attending their general practitioner (GP) practice (40 practices were involved in the trial) for a routine cervical smear.

All women tested were followed up passively using data from the national computerized system that records all smears and their results--the Open-Exeter system. Women with a smear history indicating the need for colposcopy--a more thorough examination of the cervix--were investigated further to determine whether the colposcopy and biopsy were performed, and what the resultant outcome was. Passive follow-up was complete for all women by early 2005.

Results showed that the risk of developing cervical abnormalities at one, five, and nine years after a normal smear test was 0.33%, 0.83%, and 2.20% respectively, with those odds significantly reduced after a negative HPV test--0.19%, 0.42%, and 1.88%, respectively.

The study was led by Prof. Jack Cuzick of Barts and The London School of Medicine and Dentistry (London, UK) and the results were published on May 15, 2008, in the International Journal of Cancer.

Prof. Cuzick said that HPV testing "offers women excellent protection from cervical abnormalities for at least six years after a negative test, compared to protection from a normal smear test which begins to wane after about three years. This suggests that the screening interval can be safely extended to at least six years with HPV testing. These data provide more support for replacing screening based on abnormal cells, with a more sensitive test based on screening for the human papillomavirus.”


Related Links:
Barts and The London School of Medicine and Dentistry

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.